Amyotrophic Lateral Sclerosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Amyotrophic Lateral Sclerosis stocks.

Amyotrophic Lateral Sclerosis Stocks Recent News

Date Stock Title
May 15 BCLI BrainStorm Cell Therapeutics GAAP EPS of -$0.05 beats by $0.02
May 15 CYTK Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
May 15 PMN ProMIS Neurosciences GAAP EPS of -$0.19
May 14 BCLI BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 14 PMN ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14 VYGR Q1 2024 Voyager Therapeutics Inc Earnings Call
May 14 COYA Coya Therapeutics, Inc.'s (NASDAQ:COYA) largest shareholders are retail investors with 60% ownership, insiders own 16%
May 14 VYGR Voyager Therapeutics, Inc. (VYGR) Q1 2024 Earnings Call Transcript
May 14 VYGR Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 13 VYGR Voyager Therapeutics up 8% following quarterly beats
May 13 CYTK Health Care Roundup: Market Talk
May 13 VYGR Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
May 13 VYGR Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02M
May 13 VYGR Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
May 13 DNLI Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13 CYTK Cytokinetics Reveals More From The Study That Boosted Shares 83%
May 13 CYTK Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
May 13 CYTK Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
May 12 DNLI Cantor picks 14 undervalued biotech stocks worth a second look
May 11 DNLI The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically
Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease, is a specific disease which causes the death of neurons controlling voluntary muscles. Some also use the term motor neuron disease for a group of conditions of which ALS is the most common. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. It may begin with weakness in the arms or legs, or with difficulty speaking or swallowing. About half of people develop at least mild difficulties with thinking and behavior and most people experience pain. Most eventually lose the ability to walk, use their hands, speak, swallow, and breathe.The cause is not known in 90% to 95% of cases, but is believed to involve both genetic and environmental factors. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.No cure for ALS is known. The goal of treatment is to improve symptoms. A medication called riluzole may extend life by about two to three months. Non-invasive ventilation may result in both improved quality and length of life. Mechanical ventilation can prolong survival but does not stop disease progression. A feeding tube may help. The disease can affect people of any age, but usually starts around the age of 60 and in inherited cases around the age of 50. The average survival from onset to death is two to four years, though this can vary. About 10% survive longer than 10 years. Most die from respiratory failure. The disease affects about two people per 100,000 per year worldwide.Descriptions of the disease date back to at least 1824 by Charles Bell. In 1869, the connection between the symptoms and the underlying neurological problems was first described by Jean-Martin Charcot, who in 1874 began using the term amyotrophic lateral sclerosis. It became well known in the United States in the 20th century when in 1939 it affected the baseball player Lou Gehrig and later worldwide following the 1963 diagnosis of cosmologist Stephen Hawking. The first ALS gene was discovered in 1993 while the first animal model was developed in 1994. In 2014, videos of the Ice Bucket Challenge went viral on the Internet and increased public awareness of the condition.

Browse All Tags